Eli Lilly’s CFO Spills the Beans Zepbound, the Weight-loss Wonder Drug, Slashes Costs by 20%!

Eli Lilly's CFO Reveals Reason for 20% Lower Price of Zepbound, the Company's Revolutionary Weight Loss Medication

Anat Ashkenazi

As a CFO, making investments to bring real innovation to the marketplace can position the company for long-term growth. But when it comes to innovation in health care, like combating obesity, the implications can impact the lives of millions of people.

“It’s important to note that obesity is not just a number on a scale,” says Anat Ashkenazi, the EVP and CFO of Eli Lilly and Company. “It has much broader health implications.” Hold your horses! We’re not talking about a random number here; we’re talking about over 110 million heavyweight champions in the United States alone. That’s right, folks, obesity is associated with over 200 health complications! It’s like fighting a boss battle with a never-ending health bar.

Now, let me introduce you to Lilly, the Indianapolis-based pharmaceutical company that’s bringing the heat in the fight against obesity. They recently announced the approval of their weight-loss drug, Zepbound, by the U.S. Food and Drug Administration. Cue the confetti cannons, folks! But hold up, this life-changing drug comes with a price tag of $1,059.87 for all six doses. Woah, talk about a heavyweight price! But fear not, my friends, if you’re covered by commercial insurance, you may be slaying that price down to as low as $25. Now that’s a deal you can’t refuse!

But hey, if Lady Luck isn’t on your side and Zepbound isn’t covered, Lilly has your back. They offer a nifty assistance program that could make your prescription cost a mere $550. That’s approximately 50% lower than the list price! They’re fighting for you, folks, making sure that innovation doesn’t just stay in the lab but reaches those who need it most.

Speaking of rivals, Lilly’s competitor, Novo Nordisk A/S, has their own obesity medication called Wegovy. But hold your applause, folks, their list price is a whopping $1,349. It’s like comparing featherweights to heavyweight champions! And here’s the knockout blow—Lilly’s Mounjaro outperforms Novo Nordisk’s Ozempic. It’s like David beating Goliath!

The demand for obesity drugs is skyrocketing, my friends. We’re talking about the global obesity market potentially reaching a whopping $77 billion in 2030. That’s like going from a small mom-and-pop shop to a multinational corporation! And in the US alone, revenue for these medications could reach a robust $70 billion. That’s a mountain of cash!

Now, let’s hear from the CFO herself, Anat Ashkenazi. She’s been with Lilly since 2001, slaying financial dragons and leading the charge. According to her, the key to a winning strategy is doubling down on innovation. It’s like playing a high-stakes game of poker—innovation is your ace up the sleeve. Even during challenging times, Lilly didn’t back down. Between 2010 and 2014, when patent expiry threatened to knock them out, they kept their focus on research and development. And guess what? They’ve been launching new products every year since 2014. Talk about resilience, my friends!

While we’re at it, let’s give a round of applause to Lars Boesgaard, the new CFO at PDS Biotechnology Corporation. He’s stepping up to the plate, ready to tackle the challenges of the clinical-stage immunotherapy company. And let’s not forget Daniel Hobbs, the EVP and CFO at Simmons First National Corporation. He’s joining the team, bringing his finance expertise to the table. The financial world never sleeps, folks!

In today’s fast-paced world, IT is the engine that keeps businesses running. And according to the 10th annual IT Enterprise Insights study, IT is becoming a crucial source of value and talent attraction. Senior IT executives are seeing increases in their budgets, ready to invest in efficient operations and tackle security like guarding a treasure chest.

Let’s take a moment to remember Charlie Munger, the investing legend who contributed significantly to Berkshire Hathaway’s success. He passed away at the age of 99, leaving behind a blueprint for the empire that Warren Buffett built. May his investing wisdom live on!

And before we wrap up, it’s time to address the elephant in the room: talent scarcity. The labor market is tightening, and the skills companies need don’t always match the skills people have. We’re facing a shortage, my friends. The need for specialization is greater than ever. So let’s buckle up and prepare for battle!

That’s it for today, my fellow finance enthusiasts! Join me next time for some more financial and economic insights. Stay curious, stay motivated, and let’s conquer the world of finance together!

-Sheryl Estrada, your friendly finance expert

Hey there! Thanks for joining me on this finance and economic rollercoaster. It’s always a wild ride, isn’t it? If you have any questions or just want to chat, feel free to drop me a message at [email protected]. Remember, finance is fun, and I’m here to help you navigate through it with a smile on your face.

Until next time, my fellow finance warriors. Keep slaying those financial dragons and making the world a better place, one dollar at a time!

-Sheryl Estrada, your partner in finance crime

Gen Z’s Work Approach A Lesson for Mi...
Morning Bid From Waller to Wall Street, Fed...
Walmart says goodbye to China and shouts Na...
The UAE’s AI Maverick CEO Admits Skip...
The Race Against Time: Repricing Assets and...
When Academia Gets Political Congress Summo...
Business

Business